This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022 | In-Person + DigitalHynes Convention Center, Boston

Dong Wei, Ph.D.
Chief Executive Officer at EdiGene


Dr. Dong Wei joined EdiGene as CEO in 2018, a biotechnology company focused on translating gene editing technologies into transformative therapies for patients with serious genetic diseases and cancer.

Prior to EdiGene, Dr. Wei had over 20 years of experience in innovative drug development and management, including leading over 10 global clinical-stage programs in multiple therapeutic areas at BioMarin, Elan, Johnson & Johnson and Shire, advising healthcare and life science clients on strategic and operational issues at Deloitte Consulting, as well as conducting drug discovery and technology development at Chiron and Applied Biosystems.

He holds BS in Genetics from Peking University, Ph.D. in Microbiology from Michigan State University and MBA from the Wharton School of University of Pennsylvania.

Agenda Sessions

  • LEAPER 2.0: In vivo RNA Base Editing with Circular ADAR-Recruiting RNA via AAV Delivery and Proof of Concept in Multiple Preclinical Models